Strategic Partnership Between Shimadzu And Sepragen

Strategic Partnership Between Shimadzu And Sepragen Corporation Expands To India

Exclusive Sales And Service Of Bioprocess Chromatography Systems Now Cover India*, Japan, South Korea, And Southeast Asia

Shimadzu (Asia Pacific) is proud to announce a significant milestone in its collaboration with Sepragen Corporation: the expansion of the strategic partnership to include India.

Widely known as the "pharmacy of the world" for its role in supplying affordable medicines globally, India is rapidly establishing itself as a global biopharma powerhouse at the forefront of innovation and growth. This extension of the partnership underscores Shimadzu’s commitment to supporting India’s dynamic biopharmaceutical sector with comprehensive, end-to-end solutions.

The Shimadzu–Sepragen partnership, first established on 25 September 2024, began with Shimadzu’s investment in Sepragen Corporation and the acquisition of exclusive rights in Japan, South Korea, and Southeast Asia. With the inclusion of India, Shimadzu further strengthens its dedication to supporting the rapidly expanding biopharmaceutical sector, particularly in the areas of human plasma fractionation and recombinant products such as insulin and their analogs, mAbs and ADCs, vaccines and gene therapy drug manufacturing.

Sepragen Corporation, founded in 1985, brings over 38 years of experience in process chromatography, with a track record of developing innovative bioprocess technologies, including radial flow chromatography for enhanced purification efficiency and chromatography systems equipped with automatic buffer preparation units. Its product portfolio, which also includes single-use components, is designed to improve customer ease, productivity, workflow, and cost, demonstrating Sepragen’s strong expertise in product development backed by advanced technology.

In biopharmaceutical production, purification is a critical step that isolates target components by separating and removing impurities. This process relies heavily on large-scale chromatography systems and consumables such as columns and resins. With the bioprocess chromatography market growing at an average annual rate of over 10%, driven by the expansion of biopharmaceuticals like vaccines and gene therapies, there is a pressing need to address challenges in scaling up purification processes and analyzing critical quality parameters of target compounds.

Shimadzu has a long-standing legacy of providing leading-edge analytical and measuring instruments, such as liquid chromatography (HPLC), for pharmaceutical research and quality control. Through this partnership with Sepragen, Shimadzu offers Total Solutions from research and development to manufacturing in the pharmaceutical sector, including biopharmaceuticals. Moving forward, Shimadzu will create synergies between its analytical technologies and Sepragen’s biomanufacturing technologies, aiming to establish robust methods for analysis and evaluation within the purification process.

The expansion aligns seamlessly with Shimadzu Corporation’s mid-term management plans, where the pharmaceutical sector stands as a core focus area. By partnering with companies that deliver pioneering technologies, Shimadzu accelerates the introduction of unique technologies and innovative products that promote sustainable and reliable biopharmaceutical manufacturing across the region.

*Shimadzu–Sepragen partnership now covers India excluding Maharashtra. For detailed information on product availability and service in India and Southeast region, please contact Shimadzu (Asia Pacific) at sales@shimadzu.com.sg